Melanotan I is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Melanotan I results typically emerge over a 60-day implant cycles; 4-8 weeks injection cycles research cycle. Early changes may be noticeable within the first 1-2 weeks, with more significant effects on skin pigmentation appearing by weeks 4-8. Results depend on dosage (16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing)), consistency, and individual factors.
What Results Can You Expect From Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning. Results depend on dosage (16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing)), administration frequency (every 60 days (implant) or daily (injection)), and individual factors.
The following timeline is based on standard 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) protocols over a 60-day implant cycles; 4-8 weeks injection cycles cycle.
What Happens in Weeks 1-2 of Melanotan I?
During the first two weeks, Melanotan I is establishing baseline blood levels. With a half-life of ~2 hours circulating; implant provides 2-month depot release, steady-state concentrations are typically reached within 4-5 half-lives.
Subtle changes researchers may notice: improved skin pigmentation, better sleep quality (commonly reported across peptide protocols), and mild injection site reactions that typically resolve.
What Changes by Weeks 3-4?
By week 3-4, the biological pathways Melanotan I targets are becoming measurably activated. Selectively binds MC1R on melanocytes, triggering the cAMP-dependent signaling cascade that increases MITF transcription factor activity. This upregulates tyrosinase enzyme expression and melanin synt.
More noticeable effects on skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning begin to emerge. This is the phase where most researchers report the first clear evidence that the compound is working.
What Results Appear at Weeks 5-8?
Weeks 5-8 represent the peak response window for most Melanocortin-1 receptor (MC1R) agonist compounds. Cumulative effects of consistent every 60 days (implant) or daily (injection) dosing at 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) produce the most visible changes.
Key results during this phase typically include pronounced improvements in skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning. This is when before-and-after differences become most apparent.
How Can You Maximize Melanotan I Results?
Consistent dosing at 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) every 60 days (implant) or daily (injection) is the single biggest factor. Skipping doses or inconsistent timing significantly reduces outcomes.
Proper storage (reconstituted at 2-8°C), sourcing from COA-tested vendors, and supporting protocols (nutrition, sleep, training where applicable) all contribute to results.
Used as standalone; not typically combined with other melanocortin peptides.
Calculate Your Melanotan I Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for Melanotan I.
Open Calculator →What Is the Realistic Melanotan I Timeline?
Expect initial effects in weeks 1-2, noticeable changes by weeks 3-4, and peak results during weeks 5-8 of a 60-day implant cycles; 4-8 weeks injection cycles cycle. Melanotan I is not instant — consistent dosing and patience are required.
Melanotan I is fda-approved as scenesse for epp only (prescription). not approved for cosmetic tanning.
Complete Guide
Melanotan I : Benefits, Dosage, Side Effects & Research
Related Reading
- Melanotan I Dosage Guide
- Melanotan I Benefits
- Melanotan I Side Effects
- Melanotan I Stacking Guide
- Melanotan I Cycle Guide
- Melanotan I Research
Research-Grade Sourcing
If you're going to research Melanotan I, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is Melanotan I?
Melanotan I (Afamelanotide) is a Melanocortin-1 receptor (MC1R) agonist. Synthetic α-MSH analog developed to stimulate melanin production through selective MC1R activation. It is researched for skin pigmentation, phototoxicity reduction in EPP patients, UV-free tanning.
What is the recommended Melanotan I dosage?
Common dosages: 16 mg implant (FDA-approved); 0.025-0.3 mg/kg (research dosing) administered every 60 days (implant) or daily (injection) via subcutaneous implant (approved) or subcutaneous injection. Cycle length: 60-day implant cycles; 4-8 weeks injection cycles. Half-life: ~2 hours circulating; implant provides 2-month depot release. Use our peptide calculator for exact reconstitution math.
What are the side effects of Melanotan I?
Milder than Melanotan II: fatigue, headache, facial flushing, nausea, development or darkening of freckles/moles. Slower onset than MT-II (weeks vs days). Generally considered safer.
Is Melanotan I safe?
Melanotan I has shown a preliminary safety profile in research. FDA-approved as Scenesse for EPP only (prescription). Not approved for cosmetic tanning. All research should follow appropriate safety protocols.